Breast-conserving surgery vs. total mastectomy in patients with triple negative breast cancer in early stages: A propensity score analysis

Cruz-Ku, Gabriel De la; Valcárcel, Bryan; Morante, Zaida; Möller, Mecker G.; Lizandro, Sofia; Rebaza, Lia P.; Enríquez, Daniel; Luque, Renato; Luján-Peche, María G.; Eyzaguirre-Sandoval, Miguel Eduardo; Saavedra, Antonella; Rázuri, César; Pinto, Joseph A.; Fuentes, Hugo; Neciosup, Silvia P.; Gómez, Henry L.

doi:10.3233/bd-190391

Cited by 9 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown that breast conserving surgery is safe and effective for early TNBC patients. Compared with modified radical surgery, breast conserving surgery can significantly shorten postoperative recovery time, reduce surgical complications and improve postoperative quality of life for patients [13].…”

Section: Tnbc's Traditional Treatmentmentioning

confidence: 99%

Research Status of Immune Microenvironment in Triple Negative Breast Cancer

Liang

2023

SHS Web of Conf.

View full text Add to dashboard Cite

Triple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, with limited treatment options and high rates of recurrence and metastasis due to the lack of specific therapeutic targets. The incidence of bone metastases and brain metastases is also high. They are more likely to relapse and have a poor long-term prognosis. The tumor microenvironment (TME) consists of tumor cells, a variety of mesenchymal cells and an extracellular matrix, which together induce tumor proliferation, stimulate angiogenesis, inhibit cell apoptosis and regulate the immune system, thereby blocking TNBC’s anti-tumor response and promote TNBC’s progression and metastasis. TNBC has unique TME, and TME may be a potential therapeutic target for TNBC. However, the overall pattern of TME phenotypes remains unknown. Because microenvironment cells have dense crosstalk, it is more reasonable to consider them as a whole. This article will review the TME characteristics of TNBC and the latest progress of TNBC microenvironment immunotherapy.

show abstract

Section: Tnbc's Traditional Treatmentmentioning

confidence: 99%

Research Status of Immune Microenvironment in Triple Negative Breast Cancer

Liang

2023

SHS Web of Conf.

View full text Add to dashboard Cite

show abstract

“…Lumpectomy and mastectomy are two common surgical treatments for all breast cancers, including TNBC [30]. The presentation of TNBC on magnetic resonance imaging (MRI) is usually a unifocal mass lesion without pervasive intraductal spread [31], which makes it suitable for lumpectomy with negative resection margins [32].…”

Section: Surgerymentioning

confidence: 99%

“…The presentation of TNBC on magnetic resonance imaging (MRI) is usually a unifocal mass lesion without pervasive intraductal spread [31], which makes it suitable for lumpectomy with negative resection margins [32]. Retrospective analysis investigating the correlation between overall survival (OS) and disease-free survival (DFS) with lumpectomy and mastectomy concluded that lumpectomy is a safe alternative to mastectomy for early-stage TNBC patients [30]. Interestingly, the recurrence rate does not vary among patients who underwent lumpectomy or total mastectomy [33,34].…”

Section: Surgerymentioning

confidence: 99%

Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs

Siddharth

Sharma

2021

Cancers

View full text Add to dashboard Cite

Metastatic progression and tumor recurrence pertaining to TNBC are certainly the leading cause of breast cancer-related mortality; however, the mechanisms underlying TNBC chemoresistance, metastasis, and tumor relapse remain somewhat ambiguous. TNBCs show 77% of the overall 4-year survival rate compared to other breast cancer subtypes (82.7 to 92.5%). TNBC is the most aggressive subtype of breast cancer, with chemotherapy being the major approved treatment strategy. Activation of ABC transporters and DNA damage response genes alongside an enrichment of cancer stem cells and metabolic reprogramming upon chemotherapy contribute to the selection of chemoresistant cells, majorly responsible for the failure of anti-chemotherapeutic regime. These selected chemoresistant cells further lead to distant metastasis and tumor relapse. The present review discusses the approved standard of care and targetable molecular mechanisms in chemoresistance and provides a comprehensive update regarding the recent advances in TNBC management.

show abstract